Abstract
We report the case of a 2-year-old boy with hypereosinophilia who presented with fever, muscle pain and heart, CNS and skin involvement. He was treated with steroids with partial response. Six months after diagnosis of hypereosinophilia, several scalp nodules were surgically removed and Hypoderma bovis larvae were found, which led to the diagnosis of cutaneous myiasis. Following removal of the larvae, the clinical and hematological manifestations returned to normal.
References
1.
Reilly A, Becker J, Meyer J, Rackoff W: Hypereosinophilia. Med Pediatr Oncol 1992;20:232–239.
2.
Jameson MD, Segraves SD: Idiopathic hypereosinophilic syndrome. Postgrad Med 1988; 84:93–101.
3.
Moore PM, Harley JB, Fauci AS: Neurologic dysfunction in the idiopathic hypereosinophilic syndrome. Ann Intern Med 1985;102:109–114.
4.
Weller PF, Bubley GJ: The idiopathic hypereosinophilic syndrome. Blood 1994;83:2759–2779.
5.
Chusid MJ, Dale DC, West BC, Wolff SM: The hypereosinophilic syndrome: Analysis of fourteen cases with review of the literature. Medicine 1975;54:1–27.
6.
Blatt J, Proujansky R, Horn M, Phebus C, Longwoth D, Penchansky L: Idiopathic hypereosinophilic syndrome terminating in acute lymphoblastic leukemia. Pediatr Hematol Oncol 1992;9:151–155.
7.
Michel G, Thuret I, Capodano AM, Scheiner C, Guitard AM, Mozziconacci MJ, Fossat C, Perrimond H: Myelofibrosis in a child suffering from a hypereosinophilic syndrome with trisomy 8: Response to corticotherapy. Med Pediatr Oncol 1991;19:62–65.
8.
San José A, Bosch JA, Candell J, Pinar J, Torrabadella M, Vallespí T, Oristrell J, Vilardell M: Afección cardíaca y hematológica en el síndrome hipereosinofílico idiopático. Estudio de 12 casos. Med Clin (Barc) 1992;98:161–165.
9.
Segura J, Anguita M, Mesa D, Romo E, Vivancos R, Suárez de Lezo J, Vallés F: Pericarditis aguda como manifestación clínica inicial del síndrome hipereosinófilo. Rev Esp Cardiol 1991;44:625–627.
10.
Ashok Kumar K, Anjaneyuyu A, Murthy JMK: Idiopathic hypereosinophilia syndrome presenting as childhood hemiplegia. Postgrad Med J 1992;68:831–833.
11.
Gordon PM, Hepburn NC, Williams AE, Bunney MH: Cutaneous myiasis due to Dermatobia hominis: A report of six cases. Br J Dermatol 1995;132:811–814.
12.
Jelinek T, Nothdurft HD, Rieder N: Cutaneous myiasis: Review of 13 cases in travelers returning from tropical countries. Int J Dermatol 1995;34:624–626.
13.
Kpea N, Zywocinski C: ‘Flies in the flesh’: A case report and review of cutaneous myiasis. Cutis 1995;55:47–48.
14.
Ruiz I, Soler MD, Perez JM, Díaz M, Sebastián J: Miasis cutánea semiespecífica mixta. Rev Clín Esp 1992;191:141–143.
15.
Añaños G, Abós R, Corachán M: Myiasis importada: análisis de 5 casos. Enferm Infecc Microbiol Clín 1989;7:421–423.
16.
Hampel H, Putz A, Müller N: Major depression following myiasis with hypereosinophilic syndrome. J Clin Psychiatry 1995;56:333–334.
17.
Uttamchandani RB, Trigo LM, Poppiti RJ Jr, Rozen S, Ratzan KR: Eosinophilic pleural effusion in cutaneous myiasis. South Med J 1989;82:1288–1291.
18.
Kalelioglu M, Artürk G, Artürk F, Komsuoglu SS, Kuzeyli K, Tigin Y, Karaer Z, Bingöl R: Intracerebral myiasis from Hypoderma bovis larva in a child. J Neurosurg 1989;71:929–931.
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
